Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial (Oellerich et al. AACC 2018)

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Schütz E et al. Graft-derived cell-free DNA – a promising rejection marker in cardiac transplantation – Results from a prospective observational trial. 69th AACC Annual Scientific Meeting Abstract eBook (2017):A-121

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Schütz E et al. Graft-derived cell-free DNA a promising Rejection Marker in Liver transplantation Results from a prospective Multicenter Trial. Clin Chem (2016): suppl. A121

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. A new universal multiplex digital PCR method with improved precision for the quantification of donor derived graft DNA traces Clin Chem (2015): suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Early Detection of Rejection after Heart Transplantation by a universal digital PCR method Clin Chem (2015): suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Use Of Plasma GcfDNAQuantification To Guide Personalized Immunosuppression. Transplant International 27 (2014): 50

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Absolute Quantification of Graft derived cell-free DNA (GcfDNA) early after Liver Transplantation (LTx) using droplet Digital PCR. Clin Chem 2015: suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | May 13th, 2017|Peer-reviewed medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | May 12th, 2017|Peer-reviewed medical publications|0 Comments

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments